Oligonucleotide (Antisense oligonucleotide) · Gene silencing: prekallikrein (RIPK4) · developed by Ionis Pharms
Donidalorsen is an antisense oligonucleotide conjugate that reduces prekallikrein (PKK) protein production by binding to PKK mRNA and triggering RNase H1-mediated degradation. By lowering PKK levels, it prevents excessive bradykinin generation and angioedema attacks in hereditary angioedema.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Sep 24, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05392114 | Phase 3 | Hereditary Angioedema | Active not recruiting | IONS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hereditary Angioedema
Updated Oct 3, 2026. Something wrong or missing? Report it on the IONS page.
See IONS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IONS catalysts and pipeline →